Epigenetics Market Size & Growth Forecast to 2030

Epigenetics Market by Product & Service (Enzymes, Kits & Reagents (Antibodies), Software), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR), Application (Oncology, Immunology, Developmental Biology), End User - Global Forecast to 2030

USD 4.29

MARKET SIZE, 2030

CAGR 13.9%

(2025-2030)

487

REPORT PAGES

627

MARKET TABLES

OVERVIEW

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global epigenetics market is projected to reach USD 4.29 billion by 2030 from USD 2.24 billion in 2025, at a CAGR of 13.9% during the forecast period of 2025-2030. The major factors driving the growth in epigenetics market includes reduced sequencing costs and accelerated turnaround times to improve access and affordability of epigenetic analysis. Additionally, growth in epigenetics market is being facilitated by increasing population screening programs, increasing demand for epigenetics-based therapeutics & diagnostics, and advances in technology that are facilitating new applications in disease diagnosis and treatment.

KEY TAKEAWAYS

North America epigenetics market accounted for the largest share of 41.6% in 2024.
Based on offering, the kits & reagents segment dominated the epigenetics market with a share of 59.8% in 2024.
By technology, the PCR & qPCR segment is projected to grow at the fastest rate from 2025 to 2030.
By method, the DNA methylation segment accounted for the largest share of 56.1% of the epigenetics market.
Based on application, the oncology segment led the global epigentetics market share.
Based on end user for products, the pharmaceutical & biotechnology companies will grow the fastest during the forecast period.
Based on end user for services,the academic & research segment is expected to grow at fastest rate during the forecast period.
Illumina, Inc., Thermo Fisher Scientific Inc., and Merck KGaA were identified as some of the star players in the epigenetics market (global), given their strong market share and product/service footprint.
Companies such as, EpiCypher, Fios Genomics, Biomodal, among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders

The epigenetics market is projected to grow significantly over the next decade, driven by various factors, such as, declining sequencing cost & time, rising demand for epigenetic drugs & epigenetics-based diagnostics, and expansion of population screening programs. Furthermore, technological advancements in epigenetic research are likely to uplift the market growth in the coming years.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The epigenetics market is undergoing a structural transformation driven by advancements in multi-omics data integration, high-throughput analysis, and reproducible workflows. The revenue mix is shifting from conventional kits and reagents toward technology-enabled solutions, new product offerings, and service-based models. Key stakeholders, including pharmaceutical and biotechnology companies, CROs, hospitals, and academic institutes, are emphasizing novel biomarker discovery, clinical validation, and regulatory-compliant workflows. These developments are resulting in enhanced diagnostic precision, accelerated drug discovery, improved translational potential, and superior patient outcomes through personalized and data-driven therapeutic approaches.

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers

Impact
Level

Declining sequencing costs and time
Growing emphasis on population screening programs

RESTRAINTS

Impact
Level

Limited applications of epigenomic data in toxicology
Data privacy concerns and security issues

OPPORTUNITIES

Impact
Level

Emerging applications of epigenetics
Integration of multi-omics

CHALLENGES

Impact
Level

Concerns regarding quality of antibodies
Challenges associated with epigenetic editing

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Declining sequencing costs and time

Advancements in sequencing technologies have significantly reduced costs and processing time, enabling broader access to high-throughput epigenomic analysis. These improvements are facilitating larger studies, data integration across omics platforms, and expanded adoption in both research and clinical applications.

Restraint: Limited applications of epigenomic data in toxicology

The adoption of epigenomic data in toxicology remains limited due to the lack of standardized methods and regulatory validation. Existing toxicological frameworks continue to rely on conventional endpoints, restricting the integration of epigenetic markers in safety and risk assessments.

Opportunity: Emerging applications of epigenetics

New applications of epigenetics are emerging in areas such as oncology, precision medicine, and developmental biology. Integration with AI and single-cell sequencing is enhancing biomarker discovery and disease stratification, expanding the scope of epigenetic research and diagnostics.

Challenge: Concerns regarding quality of antibodies

Variability in antibody specificity and reproducibility poses challenges to data reliability in epigenetic assays. The absence of standardized validation and quality benchmarks affects experimental consistency, emphasizing the need for improved quality control in reagent manufacturing.

Epigenetics Market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY	USE CASE DESCRIPTION	BENEFITS
	Uses targeted epigenetic assays for population-scale studies on environmental exposure and disease correlation.	Enables high-throughput, cost-effective population epigenomics for public health applications.
	Applies epigenetic screening in newborn testing and developmental disorder research using methylation analysis tools.	Supports early identification of developmental anomalies and enhances screening accuracy.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The epigenetics market ecosystem comprises raw material suppliers (Sigma-Aldrich, Thermo Fisher Scientific), product manufacturers (Illumina, New England Biolabs), service providers (Zymo Research, EpigenDx), regulatory bodies (US Food and Drug Administration, European Medicines Agency), and end users (Pfizer, Harvard University). Raw materials and reagents enable experiments in DNA methylation, histone modification, and chromatin accessibility. Product manufacturers and service providers offer kits, sequencing platforms, and epigenomic analysis services, supporting both research and clinical applications. End users prioritize accuracy, reproducibility, and regulatory compliance, driving adoption of advanced platforms. Collaboration across stakeholders promotes innovation, workflow integration, and expansion of therapeutic and diagnostic applications.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Epigenetics Market, By Offering

In 2024, the kits & reagents segment accounted for the largest share of the epigenetics market. Factors such as the broadening applications of chromatin immunoprecipitation (ChIP) in research studies and the increasing prominence of epigenetics research in drug discovery, development, and clinical applications are expected to drive the market growth.

Epigenetics Market, By Technology

In 2024, the NGS segment accounted for the largest share of the epigenetics market. NGS-based studies offer a comprehensive analysis of epigenetic modifications for genomes. The growing demand for better data has driven interest in the NGS segment and supported market growth.

Epigenetics Market, By Application

In 2024, the oncology segment accounted for the largest share of the epigenetics market. The high prevalence of cancer and the increasing research activities to discover and develop cancer drugs drive strong demand in this segment.

REGION

Asia Pacific to be fastest-growing region in global epigenetics market during forecast period

The Asia Pacific epigenetics market is expected to register the highest CAGR during the forecast period, primarily due to the growing pharmaceutical industry, the implementation of favorable government policies, the increasing number of newly established manufacturing facilities, and the low cost of epigenetic consumables in the region.

Epigenetics Market: COMPANY EVALUATION MATRIX

Illumina, Inc. (Star) leads the epigenetics market with a strong portfolio of sequencing platforms, methylation arrays, and integrated bioinformatics solutions that enable high-precision DNA methylation and chromatin analysis. Continuous innovation in next-generation sequencing accuracy, throughput, and cost-efficiency, combined with a robust global supply network and regulatory reliability, has reinforced its leadership across oncology, reproductive health, and personalized medicine applications. PacBio (Emerging Leader) is rapidly expanding its footprint through advanced long-read sequencing technologies that enable direct detection of epigenetic modifications without chemical treatment, driving adoption in complex methylation and chromatin studies. The company's focus on real-time analysis, strategic collaborations, and multiomic integration positions PacBio to progress toward the leaders’ quadrant as demand for comprehensive, high-resolution epigenetic solutions continues to rise globally.

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC	DETAILS
Market Size in 2024 (Value)	USD 2.03 Billion
Market Forecast in 2030 (Value)	USD 4.29 Billion
Growth Rate	CAGR of 13.9% from 2025 to 2030
Years Considered	2023–2030
Base Year	2024
Forecast Period	2025–2030
Units Considered	Value (USD Million/USD Billion)
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Offering: Kits & Reagents Enzymes Instruments & Accessories Software Services By Technology: Next-generation Sequencing PCR & qPCR Mass Spectrometry Sonication Other Techniques By Method: DNA Methylation Histone Modifications Other Methods By Application: Oncology Metabolic Diseases Immunology Developmental Biology Cardiovascular Diseases Other Applications By End User (Product): Academic & Research Institutes Pharmaceutical & Biotechnology Companies Hospitals & Clinics Contrcat Research Organizations By End User (Service): Pharmaceutical & Biotechnology Companies Academic & Research Institutes Hospitals & Clinics
Regions Covered	North America, Asia Pacific, Europe, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: Epigenetics Market REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST	CUSTOMIZATION DELIVERED	VALUE ADDS
Rest of Europe Breakdown	Country-level market sizing and growth forecasts (Sweden, Switzerland, Turkey, the Netherlands, Norway, Poland, Portugal, Romania, Denmark, Estonia, Finland, the Czech Republic, Greece, Austria, Belgium, and Russia)	Provides granular country-level insights, enabling clients to prioritize high-growth markets, and tailor portfolio strategies across products for maximum regional impact
Company Evaluation	Detailed analysis and profiling of top five market players Portfolio assessment of top five companies	Delivers visibility into competitors, helping clients identify partners, evaluate positioning, and detect market gaps for smarter collaboration, outsourcing, and strategic market entry decisions

RECENT DEVELOPMENTS

April 2025 : QIAGEN announced the launch of new QIAseq Multimodal Cancer Genomics Panels at the AACR Annual Meeting 2025. These panels are designed to advance cancer genomic profiling by enabling comprehensive analysis of key biomarkers across DNA and RNA, supporting applications such as targeted oncology research, biomarker discovery, and translational medicine. The product expands QIAGEN's NGS portfolio with streamlined workflows for higher sensitivity and accuracy in detecting clinically relevant variants.
January 2025 : New England Biolabs launched the EM-seq v2 kit, a high-performance enzyme-based alternative to bisulfite sequencing to identify 5mC and 5hmC.
October 2024 : PacBio collaborated with the Agency for Science, Technology and Research and Macrogen to launch a state-of-the-art sequencing lab in Singapore to advance genomics innovation in Asia. The facility will leverage PacBio's Revio system to support research in human health, biodiversity, and precision medicine, establishing Singapore as a hub for high-throughput long-nread and short-read sequencing technologies.
July 2024 : Thermo Fisher Scientific Inc. acquired Olink, a leading provider of next-generation proteomics solutions. This acquisition fosters the life science segment of Thermo Fisher Scientific.

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE

PAGE NO

INTRODUCTION

RESEARCH METHODOLOGY

EXECUTIVE SUMMARY

PREMIUM INSIGHTS

MARKET OVERVIEW

Epigenetics market thrives on declining sequencing costs, multi-omics integration, and therapeutic demand growth.

5.1

INTRODUCTION

5.2

MARKET DYNAMICS

5.2.1

DRIVERS

5.2.1.1

Declining sequencing costs and time

5.2.1.2

Growing emphasis on population-scale screening initiatives

5.2.1.3

Technological advancements in epigenetics research

5.2.1.4

Rising demand for epigenetic drugs and epigenetic-based therapeutics

5.2.2

RESTRAINTS

5.2.2.1

Limited applications of epigenomic data in toxicology

5.2.2.2

Data privacy concerns and security issues

5.2.3

OPPORTUNITIES

5.2.3.1

Emerging applications of epigenetics

5.2.3.2

Integration of multi-omics

5.2.4

CHALLENGES

5.2.4.1

Concerns regarding quality of antibodies

5.2.4.2

Challenges associated with epigenetic editing

5.3

TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

5.4

PRICING ANALYSIS

5.4.1

AVERAGE SELLING PRICE TREND, BY KEY PLAYER

5.4.2

AVERAGE SELLING PRICE TREND, BY REGION

5.5

VALUE CHAIN ANALYSIS

5.6

ECOSYSTEM ANALYSIS

5.7

INVESTMENT AND FUNDING SCENARIO

5.8

TECHNOLOGY ANALYSIS

5.8.1

KEY TECHNOLOGIES

5.8.1.1

Single-cell sequencing

5.8.1.2

Chromatin immunoprecipitation

5.8.2

COMPLEMENTARY TECHNOLOGIES

5.8.2.1

DNA methylation microarrays

5.8.2.2

CRISPR-based genome editing

5.9

PATENT ANALYSIS

5.10

TRADE DATA ANALYSIS

5.10.1

IMPORT DATA

5.10.2

EXPORT DATA

5.11

KEY CONFERENCES AND EVENTS, 2025–2026

5.12

TARIFF AND REGULATORY LANDSCAPE

5.12.1

TARIFF DATA FOR HS CODES 9027.50.80 AND 3822.00

5.12.2

REGULATORY FRAMEWORK

5.12.3

REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.13

PORTER’S FIVE FORCES ANALYSIS

5.13.1

BARGAINING POWER OF SUPPLIERS

5.13.2

BARGAINING POWER OF BUYERS

5.13.3

THREAT OF NEW ENTRANTS

5.13.4

THREAT OF SUBSTITUTES

5.13.5

INTENSITY OF COMPETITIVE RIVALRY

5.14

KEY STAKEHOLDERS AND BUYING CRITERIA

5.14.1

KEY STAKEHOLDERS IN BUYING PROCESS

5.14.2

KEY BUYING CRITERIA

5.15

IMPACT OF AI/GEN AI ON EPIGENETICS MARKET

5.15.1

INTRODUCTION

5.15.2

MARKET POTENTIAL OF AI IN EPIGENETICS

5.15.3

AI USE CASES

5.15.4

KEY COMPANIES IMPLEMENTING AI/GEN AI

5.15.5

FUTURE OF AI/GEN AI IN EPIGENETICS MARKET

5.16

IMPACT OF 2025 US TARIFF

5.16.1

INTRODUCTION

5.16.2

KEY TARIFF RATES

5.16.3

PRICE IMPACT ANALYSIS

5.16.4

KEY IMPACTS ON VARIOUS REGIONS

5.16.4.1

5.16.4.2

Europe

5.16.4.3

Asia Pacific

5.16.5

END-USE INDUSTRY IMPACT

5.16.5.1

Pharmaceutical and biotech companies

5.16.5.2

Contract Research Organizations (CROs)

5.16.5.3

Academic and research institutes

EPIGENETICS MARKET, BY OFFERING

Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 108 Data Tables

116

6.1

INTRODUCTION

6.2

KITS & REAGENTS

6.2.1

ANTIBODIES

6.2.1.1

Growing demand for recombinant antibodies for detection of epigenetic targets to propel market

6.2.2

CHIP-SEQUENCING KITS & REAGENTS

6.2.2.1

Versatile applications of chromatin immunoprecipitation pertaining to epigenetic regulatory systems to boost market

6.2.3

BISULFITE CONVERSION KITS & REAGENTS

6.2.3.1

Effective outcomes associated with bisulfite conversion to sustain growth

6.2.4

WHOLE-GENOME AMPLIFICATION KITS & REAGENTS

6.2.4.1

Ability to maintain relative proportions of genes in original pool to stimulate growth

6.2.5

5-HMC & 5-MC ANALYSIS KITS & REAGENTS

6.2.5.1

Introduction of unique kits for 5-mC and 5-hmC analysis to support growth

6.2.6

HISTONES

6.2.6.1

Emerging importance of chromatin-associated proteins and histones in epigenetic research to bolster growth

6.2.7

OTHER KITS & REAGENTS

6.3

ENZYMES

6.3.1

DNA-MODIFYING ENZYMES

6.3.1.1

Broadening applications of DNA methylation to facilitate growth

6.3.2

PROTEIN-MODIFYING ENZYMES

6.3.2.1

Increasing pipeline of epigenetics-based drugs targeting histone-modifying enzymes to spur growth

6.3.3

OTHER ENZYMES

6.4

INSTRUMENTS & ACCESSORIES

6.4.1

WIDE USAGE OF NGS INSTRUMENTS AND SONICATORS TO EXPEDITE GROWTH

6.5

SOFTWARE

6.5.1

DEVELOPMENT OF VIABLE SOFTWARE SOLUTIONS FOR DNA METHYLATION AND RNA ANALYSIS TO PROMOTE GROWTH

6.6

SERVICES

6.6.1

EXPANDING POOL OF SERVICE PROVIDERS TO DRIVE MARKET

EPIGENETICS MARKET, BY TECHNOLOGY

Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 36 Data Tables

171

7.1

INTRODUCTION

7.2

NEXT-GENERATION SEQUENCING (NGS)

7.2.1

INCREASING LAUNCHES OF NEXT-GENERATION SEQUENCING PLATFORMS TO FACILITATE GROWTH

7.3

PCR & QPCR

7.3.1

RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE MARKET

7.4

MASS SPECTROMETRY

7.4.1

GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET

7.5

SONICATION

7.5.1

RISING USE OF SONICATION IN SCIENTIFIC AND INDUSTRIAL SETTINGS TO EXPEDITE GROWTH

7.6

OTHER TECHNOLOGIES

EPIGENETICS MARKET, BY METHOD

Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 23 Data Tables

192

8.1

INTRODUCTION

8.2

DNA METHYLATION

8.2.1

INCREASING RESEARCH & DEVELOPMENT ACTIVITIES TO SPUR GROWTH

8.3

HISTONE MODIFICATIONS

8.3.1

GROWING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET

8.4

OTHER METHODS

EPIGENETICS MARKET, BY APPLICATION

Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 44 Data Tables

204

9.1

INTRODUCTION

9.2

ONCOLOGY

9.2.1

GROWING INVESTMENT IN EPIGENETIC-BASED RESEARCH TO BOOST MARKET

9.3

METABOLIC DISEASES

9.3.1

EMERGING ROLE OF DNA METHYLATION IN DIABETES MANAGEMENT TO FAVOR GROWTH

9.4

IMMUNOLOGY

9.4.1

GROWING DEMAND FOR EPIGENETIC PRODUCTS IN TUMOR AND TRANSPLANTATION IMMUNOLOGY TO DRIVE MARKET

9.5

DEVELOPMENTAL BIOLOGY

9.5.1

INCREASING RESEARCH ON CELL GROWTH AND DIFFERENTIATION TO PROPEL MARKET

9.6

CARDIOVASCULAR DISEASES

9.6.1

EMERGING ROLE OF EPIGENETICS IN UNDERSTANDING ETIOLOGY OF CARDIOVASCULAR DISEASES TO AID GROWTH

9.7

OTHER APPLICATIONS

EPIGENETICS PRODUCTS MARKET, BY END USER

Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 29 Data Tables

229

10.1

INTRODUCTION

10.2

ACADEMIC & RESEARCH INSTITUTES

10.2.1

INCREASING PUBLIC-PRIVATE COLLABORATIONS TO FAVOR GROWTH

10.3

PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

10.3.1

GROWING NUMBER OF CLINICAL TRIALS FOR EPIGENETIC-BASED DRUGS TO FUEL MARKET

10.4

HOSPITALS & CLINICS

10.4.1

GROWING USE OF PERSONALIZED MEDICINE TO PROPEL MARKET

10.5

CONTRACT RESEARCH ORGANIZATIONS

10.5.1

INCREASING DEMAND FOR SCALABLE, HIGH-THROUGHPUT EPIGENETICS KITS TO PROMOTE GROWTH

EPIGENETICS SERVICE MARKET, BY END USER

Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 22 Data Tables

246

11.1

INTRODUCTION

11.2

PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

11.2.1

RISING DEMAND FOR THERAPEUTIC DISCOVERIES TO BOLSTER GROWTH

11.3

ACADEMIC & RESEARCH INSTITUTES

11.3.1

INCREASING VOLUME OF HIGH-THROUGHPUT EPIGENOMIC DATA TO AUGMENT GROWTH

11.4

HOSPITALS & CLINICS

11.4.1

INCREASING INTEGRATION OF EPIGENETIC ASSAYS INTO CLINICAL DIAGNOSTICS, PROGNOSTICS, AND PERSONALIZED MEDICINE TO AID GROWTH

EPIGENETICS MARKET, BY REGION

Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 265 Data Tables

258

12.1

INTRODUCTION

12.2

NORTH AMERICA

12.2.1

MACROECONOMIC OUTLOOK FOR NORTH AMERICA

12.2.2

12.2.2.1

Strong network of well-established epigenetic product manufacturers to spur growth

12.2.3

CANADA

12.2.3.1

Favorable government initiatives to contribute to growth

12.3

EUROPE

12.3.1

MACROECONOMIC OUTLOOK FOR EUROPE

12.3.2

GERMANY

12.3.2.1

Significant investments in next-generation sequencing to bolster growth

12.3.3

12.3.3.1

Rising acceptance of genome-based diagnostic techniques to support growth

12.3.4

FRANCE

12.3.4.1

Growing demand for PCR technologies to drive market

12.3.5

ITALY

12.3.5.1

High incidence of cancer to expedite growth

12.3.6

SPAIN

12.3.6.1

Well-established network of research centers and universities to boost market

12.3.7

REST OF EUROPE

12.4

ASIA PACIFIC

12.4.1

MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

12.4.2

CHINA

12.4.2.1

High demand for personalized medicine to accelerate growth

12.4.3

JAPAN

12.4.3.1

Increasing collaborations between research & academic organizations to favor growth

12.4.4

INDIA

12.4.4.1

Expanding base of biotechnology facilities to drive market

12.4.5

AUSTRALIA

12.4.5.1

Growing hub for epigenetics to propel market

12.4.6

SOUTH KOREA

12.4.6.1

Rising burden of chronic diseases to foster growth

12.4.7

REST OF ASIA PACIFIC

12.5

LATIN AMERICA

12.5.1

MACROECONOMIC OUTLOOK FOR LATIN AMERICA

12.5.2

BRAZIL

12.5.2.1

Increasing number of healthcare providers incorporating epigenetic testing to aid growth

12.5.3

MEXICO

12.5.3.1

Growing adoption of cutting-edge technologies to drive market

12.5.4

REST OF LATIN AMERICA

12.6

MIDDLE EAST

12.6.1

MACROECONOMIC OUTLOOK FOR MIDDLE EAST

12.6.2

GCC COUNTRIES

12.6.2.1

Saudi Arabia

12.6.2.2

UAE

12.6.2.3

Rest of GCC countries

12.6.3

REST OF MIDDLE EAST

12.7

AFRICA

12.7.1

RISING DEMAND FOR TARGETED THERAPIES TO AUGMENT GROWTH

12.7.2

MACROECONOMIC OUTLOOK FOR AFRICA

COMPETITIVE LANDSCAPE

Uncover strategic insights and market positions of leading and emerging players in the competitive landscape.

393

13.1

INTRODUCTION

13.2

KEY PLAYER STRATEGIES

13.3

REVENUE ANALYSIS

13.4

MARKET SHARE ANALYSIS

13.5

COMPANY VALUATION AND FINANCIAL METRICS

13.6

BRAND/PRODUCT COMPARISON

13.6.1

THERMO FISHER SCIENTIFIC INC.

13.6.2

ILLUMINA, INC.

13.6.3

MERCK KGAA

13.6.4

DANAHER

13.7

COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024

13.7.1

STARS

13.7.2

EMERGING LEADERS

13.7.3

PERVASIVE PLAYERS

13.7.4

PARTICIPANTS

13.7.5

COMPANY FOOTPRINT: KEY PLAYERS, 2024

13.7.5.1

Company footprint

13.7.5.2

Region footprint

13.7.5.3

Offering footprint

13.7.5.4

Method footprint

13.7.5.5

Technology footprint

13.8

COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024

13.8.1

PROGRESSIVE COMPANIES

13.8.2

RESPONSIVE COMPANIES

13.8.3

DYNAMIC COMPANIES

13.8.4

STARTING BLOCKS

13.8.5

COMPETITIVE BENCHMARKING

13.8.5.1

Detailed list of key startups/SMEs

13.8.5.2

Competitive benchmarking of key startups/SMEs

13.9

COMPETITIVE SCENARIO

13.9.1

PRODUCT LAUNCHES

13.9.2

DEALS

13.9.3

EXPANSIONS

COMPANY PROFILES

In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)

413

14.1

KEY MARKET PLAYERS

14.1.1

THERMO FISHER SCIENTIFIC INC.

14.1.1.1

Business overview

14.1.1.2

Products offered

14.1.1.3

Recent developments

14.1.1.4

MnM view

14.1.2

ILLUMINA, INC.

14.1.3

MERCK KGAA

14.1.4

PACBIO

14.1.5

DANAHER

14.1.6

BIO-RAD LABORATORIES, INC.

14.1.7

ACTIVE MOTIF

14.1.8

NEW ENGLAND BIOLABS

14.1.9

QIAGEN

14.1.10

ZYMO RESEARCH CORPORATION

14.1.11

REVVITY

14.1.12

HOLOGIC, INC.

14.1.13

F. HOFFMANN-LA ROCHE LTD

14.1.14

PROMEGA CORPORATION

14.1.15

EPIGENTEK GROUP INC.

14.2

OTHER PLAYERS

14.2.1

EPICYPHER

14.2.2

FIOS GENOMICS

14.2.3

GENOMESCAN

14.2.4

CREATIVE BIOGENE

14.2.5

BPS BIOSCIENCE, INC.

14.2.6

ABNOVA CORPORATION

14.2.7

CREATIVE DIAGNOSTICS

14.2.8

BIOMODAL

14.2.9

INTEGRATED DNA TECHNOLOGIES, INC.

14.2.10

NOVOGENE CO., LTD.

APPENDIX

482

15.1

DISCUSSION GUIDE

15.2

KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL

15.3

CUSTOMIZATION OPTIONS

15.4

RELATED REPORTS

15.5

AUTHOR DETAILS

LIST OF TABLES

TABLE 1

EPIGENETICS MARKET: INCLUSIONS AND EXCLUSIONS

TABLE 2

IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS

TABLE 3

EPIGENETICS MARKET: RISK ANALYSIS

TABLE 4

EPIGENETICS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS

TABLE 5

AVERAGE SELLING PRICE TREND OF EPIGENETIC PRODUCTS, BY KEY PLAYER, 2022–2024 (USD MILLION)

TABLE 6

AVERAGE SELLING PRICE TREND OF EPIGENETIC INSTRUMENTS, BY REGION, 2022–2024 (USD MILLION)

TABLE 7

AVERAGE SELLING PRICE TREND OF EPIGENETIC KITS AND REAGENTS, BY REGION, 2022–2024 (USD MILLION)

TABLE 8

AVERAGE SELLING PRICE TREND OF EPIGENETIC ENZYMES, BY REGION, 2022–2024 (USD MILLION)

TABLE 9

EPIGENETICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM

TABLE 10

EPIGENETICS MARKET: INVESTMENT AND FUNDING SCENARIO OF KEY PLAYERS, 2022−2025

TABLE 11

EPIGENETICS MARKET: PATENTS FILED GLOBALLY, 2014−2024

TABLE 12

EPIGENETICS MARKET: LIST OF PATENTS/PATENT APPLICATIONS, 2024–2025

TABLE 13

IMPORT VALUE OF HS CODE 9027.50– COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)

TABLE 14

IMPORT VALUE OF HS CODE 382.00– COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)

TABLE 15

EXPORT VALUE OF HS CODE 9027.50 – COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)

TABLE 16

EXPORT VALUE OF HS CODE 3822.00 – COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)

TABLE 17

EPIGENETICS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026

TABLE 18

TARIFF DATA FOR HS CODES 9027.50.80 AND 3822.00

TABLE 19

KEY REGULATORY AGENCIES

TABLE 20

NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 21

EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 22

ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 23

LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 24

MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 25

AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 26

EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS

TABLE 27

INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING

TABLE 28

KEY BUYING CRITERIA, BY END USER

TABLE 29

LIST OF COMPANIES IMPLEMENTING AI/GEN AI IN EPIGENETICS MARKET

TABLE 30

US ADJUSTED RECIPROCAL TARIFF RATES

TABLE 31

EXPORTS AND IMPORTS, BY REGION, 2024–2025

TABLE 32

KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO EPIGENETICS

TABLE 33

CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES

TABLE 34

EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 35

EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 36

EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 37

NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 38

EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 39

ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 40

LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 41

MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 42

GCC COUNTRIES: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 43

EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 44

NORTH AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 45

EUROPE: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 46

ASIA PACIFIC: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 47

LATIN AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 48

MIDDLE EAST: EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 49

GCC COUNTRIES: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 50

EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 51

NORTH AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 52

EUROPE: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 53

ASIA PACIFIC: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 54

LATIN AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 55

MIDDLE EAST: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 56

GCC COUNTRIES: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 57

EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 58

NORTH AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 59

EUROPE: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 60

ASIA PACIFIC: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 61

LATIN AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 62

MIDDLE EAST: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 63

GCC COUNTRIES: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 64

EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 65

NORTH AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 66

EUROPE: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 67

ASIA PACIFIC: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 68

LATIN AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 69

MIDDLE EAST: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 70

GCC COUNTRIES: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 71

EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 72

NORTH AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 73

EUROPE: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 74

ASIA PACIFIC: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 75

LATIN AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 76

MIDDLE EAST: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 77

GCC COUNTRIES: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 78

EPIGENETICS MARKET FOR HISTONES, BY REGION, 2023–2030 (USD MILLION)

TABLE 79

NORTH AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 80

EUROPE: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 81

ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 82

LATIN AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 83

MIDDLE EAST: EPIGENETICS MARKET FOR HISTONES, BY REGION, 2023–2030 (USD MILLION)

TABLE 84

GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 85

EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 86

NORTH AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 87

EUROPE: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 88

ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 89

LATIN AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 90

MIDDLE EAST: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 91

GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 92

EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 93

EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2023–2030 (USD MILLION)

TABLE 94

NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 95

EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 96

ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 97

LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 98

MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2023–2030 (USD MILLION)

TABLE 99

GCC COUNTRIES: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 100

EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY REGION, 2023–2030 (USD MILLION)

TABLE 101

NORTH AMERICA: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 102

EUROPE: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 103

ASIA PACIFIC: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 104

LATIN AMERICA: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 105

MIDDLE EAST: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY REGION, 2023–2030 (USD MILLION)

TABLE 106

GCC COUNTRIES: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 107

EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION, 2023–2030 (USD MILLION)

TABLE 108

NORTH AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 109

EUROPE: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 110

ASIA PACIFIC: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 111

LATIN AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 112

MIDDLE EAST: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION, 2023–2030 (USD MILLION)

TABLE 113

GCC COUNTRIES: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 114

EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2023–2030 (USD MILLION)

TABLE 115

NORTH AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 116

EUROPE: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 117

ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 118

LATIN AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 119

MIDDLE EAST: EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2023–2030 (USD MILLION)

TABLE 120

GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 121

EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 122

NORTH AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 123

EUROPE: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 124

ASIA PACIFIC: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 125

LATIN AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 126

MIDDLE EAST: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 127

GCC COUNTRIES: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 128

EPIGENETICS MARKET FOR SOFTWARE, BY REGION, 2023–2030 (USD MILLION)

TABLE 129

NORTH AMERICA: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 130

EUROPE: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 131

ASIA PACIFIC: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 132

LATIN AMERICA: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 133

MIDDLE EAST: EPIGENETICS MARKET FOR SOFTWARE, BY REGION, 2023–2030 (USD MILLION)

TABLE 134

REST OF GCC COUNTRIES: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 135

EPIGENETICS MARKET FOR SERVICES, BY REGION, 2023–2030 (USD MILLION)

TABLE 136

NORTH AMERICA: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 137

EUROPE: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 138

ASIA PACIFIC: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 139

LATIN AMERICA: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 140

MIDDLE EAST: EPIGENETICS MARKET FOR SERVICES, BY REGION, 2023–2030 (USD MILLION)

TABLE 141

GCC COUNTRIES: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 142

EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 143

EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)

TABLE 144

NORTH AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 145

EUROPE: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 146

ASIA PACIFIC: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 147

LATIN AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 148

MIDDLE EAST: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)

TABLE 149

GCC COUNTRIES: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 150

EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2023–2030 (USD MILLION)

TABLE 151

NORTH AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 152

EUROPE: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 153

ASIA PACIFIC: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 154

LATIN AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 155

MIDDLE EAST: EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2023–2030 (USD MILLION)

TABLE 156

GCC COUNTRIES: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 157

EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2023–2030 (USD MILLION)

TABLE 158

NORTH AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 159

EUROPE: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 160

ASIA PACIFIC: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 161

LATIN AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 162

MIDDLE EAST: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2023–2030 (USD MILLION)

TABLE 163

GCC COUNTRIES: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 164

EPIGENETICS MARKET FOR SONICATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 165

NORTH AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 166

EUROPE: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 167

ASIA PACIFIC: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 168

LATIN AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 169

MIDDLE EAST: EPIGENETICS MARKET FOR SONICATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 170

GCC COUNTRIES: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 171

EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 172

NORTH AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 173

EUROPE: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 174

ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 175

LATIN AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 176

MIDDLE EAST: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 177

GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 178

EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 179

EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 180

NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 181

EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 182

ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 183

LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 184

MIDDLE EAST: EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 185

GCC COUNTRIES: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 186

COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS

TABLE 187

EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 188

NORTH AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 189

EUROPE: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 190

ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 191

LATIN AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 192

MIDDLE EAST: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 193

GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 194

EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2023–2030 (USD MILLION)

TABLE 195

NORTH AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 196

EUROPE: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 197

ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 198

LATIN AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 199

MIDDLE EAST: EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2023–2030 (USD MILLION)

TABLE 200

GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 201

EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 202

EPIGENOME-TARGETING CANCER DRUGS APPROVED OR IN CLINICAL TRIALS

TABLE 203

EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)

TABLE 204

NORTH AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 205

EUROPE: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 206

ASIA PACIFIC: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 207

LATIN AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 208

MIDDLE EAST: EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)

TABLE 209

GCC COUNTRIES: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 210

EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 2023–2030 (USD MILLION)

TABLE 211

NORTH AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 212

EUROPE: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 213

ASIA PACIFIC: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 214

LATIN AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 215

MIDDLE EAST: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 2023–2030 (USD MILLION)

TABLE 216

GCC COUNTRIES: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 217

EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION, 2023–2030 (USD MILLION)

TABLE 218

NORTH AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 219

EUROPE: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 220

ASIA PACIFIC: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 221

LATIN AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 222

MIDDLE EAST: EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION, 2023–2030 (USD MILLION)

TABLE 223

GCC COUNTRIES: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 224

EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2023–2030 (USD MILLION)

TABLE 225

NORTH AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 226

EUROPE: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 227

ASIA PACIFIC: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 228

LATIN AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 229

MIDDLE EAST: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2023–2030 (USD MILLION)

TABLE 230

GCC COUNTRIES: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 231

EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION)

TABLE 232

NORTH AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 233

EUROPE: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 234

ASIA PACIFIC: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 235

LATIN AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 236

MIDDLE EAST: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION)

TABLE 237

GCC COUNTRIES: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 238

EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 239

NORTH AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 240

EUROPE: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 241

ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 242

LATIN AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 243

MIDDLE EAST: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 244

GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 245

EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 246

EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)

TABLE 247

NORTH AMERICA: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 248

EUROPE: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 249

ASIA PACIFIC: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 250

LATIN AMERICA: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 251

MIDDLE EAST: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)

TABLE 252

GCC COUNTRIES: EPIGENETICS PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 253

EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 254

NORTH AMERICA: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 255

EUROPE: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 256

ASIA PACIFIC: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 257

LATIN AMERICA: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 258

MIDDLE EAST: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 259

GCC COUNTRIES: EPIGENETICS PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 260

EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2030 (USD MILLION)

TABLE 261

NORTH AMERICA: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 262

EUROPE: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 263

ASIA PACIFIC: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 264

LATIN AMERICA: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 265

MIDDLE EAST: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2030 (USD MILLION)

TABLE 266

GCC COUNTRIES: EPIGENETICS PRODUCT MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 267

EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 268

NORTH AMERICA: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 269

EUROPE: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 270

ASIA PACIFIC: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 271

LATIN AMERICA: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 272

MIDDLE EAST: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 273

GCC COUNTRIES: EPIGENETICS PRODUCT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 274

EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 275

EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 276

NORTH AMERICA: EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 277

EUROPE: EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 278

ASIA PACIFIC: EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 279

LATIN AMERICA: EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 280

MIDDLE EAST: EPIGENETICS SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 281

GCC COUNTRIES: EPIGENETICS SERVICE MARKET PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 282

EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)

TABLE 283

NORTH AMERICA: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 284

EUROPE: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 285

ASIA PACIFIC: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 286

LATIN AMERICA: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 287

MIDDLE EAST: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)

TABLE 288

GCC COUNTRIES: EPIGENETICS SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 289

EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2030 (USD MILLION)

TABLE 290

NORTH AMERICA: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 291

EUROPE: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 292

ASIA PACIFIC: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 293

LATIN AMERICA: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 294

MIDDLE EAST: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2030 (USD MILLION)

TABLE 295

GCC COUNTRIES: EPIGENETICS SERVICE MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 296

EPIGENETICS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 297

NORTH AMERICA: KEY MACROECONOMIC INDICATORS

TABLE 298

NORTH AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 299

NORTH AMERICA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 300

NORTH AMERICA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 301

NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 302

NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 303

NORTH AMERICA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 304

NORTH AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 305

NORTH AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 306

NORTH AMERICA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 307

NORTH AMERICA: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 308

US: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 309

US: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 310

US: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 311

US: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 312

US: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 313

US: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 314

US: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 315

US: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 316

US: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 317

CANADA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 318

CANADA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 319

CANADA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 320

CANADA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 321

CANADA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 322

CANADA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 323

CANADA: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 324

CANADA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 325

CANADA: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 326

EUROPE: KEY MACROECONOMIC INDICATORS

TABLE 327

EUROPE: EPIGENETICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 328

EUROPE: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 329

EUROPE: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 330

EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 331

EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 332

EUROPE: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 333

EUROPE: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 334

EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 335

EUROPE: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 336

EUROPE: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 337

GERMANY: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 338

GERMANY: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 339

GERMANY: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 340

GERMANY: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 341

GERMANY: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 342

GERMANY: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 343

GERMANY: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 344

GERMANY: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 345

GERMANY: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 346

UK: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 347

UK: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 348

UK: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 349

UK: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 350

UK: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 351

UK: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 352

UK: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 353

UK: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 354

UK: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 355

FRANCE: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 356

FRANCE: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 357

FRANCE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 358

FRANCE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 359

FRANCE: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 360

FRANCE: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 361

FRANCE: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 362

FRANCE: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 363

FRANCE: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 364

ITALY: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 365

ITALY: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 366

ITALY: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 367

ITALY: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 368

ITALY: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 369

ITALY: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 370

ITALY: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 371

ITALY: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 372

ITALY: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 373

SPAIN: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 374

SPAIN: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 375

SPAIN: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 376

SPAIN: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 377

SPAIN: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 378

SPAIN: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 379

SPAIN: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 380

SPAIN: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 381

SPAIN: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 382

REST OF EUROPE: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 383

REST OF EUROPE: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 384

REST OF EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 385

REST OF EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 386

REST OF EUROPE: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 387

REST OF EUROPE: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 388

REST OF EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 389

REST OF EUROPE: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 390

REST OF EUROPE: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 391

ASIA PACIFIC: KEY MACROECONOMIC INDICATORS

TABLE 392

ASIA PACIFIC: EPIGENETICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 393

ASIA PACIFIC: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 394

ASIA PACIFIC: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 395

ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 396

ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 397

ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 398

ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 399

ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 400

ASIA PACIFIC: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 401

ASIA PACIFIC: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 402

CHINA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 403

CHINA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 404

CHINA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 405

CHINA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 406

CHINA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 407

CHINA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 408

CHINA: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 409

CHINA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 410

CHINA: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 411

JAPAN: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 412

JAPAN: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 413

JAPAN: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 414

JAPAN: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 415

JAPAN: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 416

JAPAN: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 417

JAPAN: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 418

JAPAN: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 419

JAPAN: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 420

INDIA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 421

INDIA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 422

INDIA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 423

INDIA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 424

INDIA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 425

INDIA: EPIGENETICS MARKET, BY TECHNOLOGY 2023–2030 (USD MILLION)

TABLE 426

INDIA: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 427

INDIA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 428

INDIA: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 429

AUSTRALIA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 430

AUSTRALIA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 431

AUSTRALIA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 432

AUSTRALIA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 433

AUSTRALIA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 434

AUSTRALIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 435

AUSTRALIA: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 436

AUSTRALIA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 437

AUSTRALIA: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 438

SOUTH KOREA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 439

SOUTH KOREA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 440

SOUTH KOREA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 441

SOUTH KOREA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 442

SOUTH KOREA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 443

SOUTH KOREA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 444

SOUTH KOREA: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 445

SOUTH KOREA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 446

SOUTH KOREA: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 447

REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 448

REST OF ASIA PACIFIC: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 449

REST OF ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 450

REST OF ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 451

REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 452

REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 453

REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 454

REST OF ASIA PACIFIC: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 455

REST OF ASIA PACIFIC: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 456

LATIN AMERICA: KEY MACROECONOMIC INDICATORS

TABLE 457

LATIN AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 458

LATIN AMERICA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 459

LATIN AMERICA: EPIGENETICS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 460

LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 461

LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 462

LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 463

LATIN AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 464

LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 465

LATIN AMERICA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 466

LATIN AMERICA: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 467

BRAZIL: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 468

BRAZIL: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 469

BRAZIL: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 470

BRAZIL: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 471

BRAZIL: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 472

BRAZIL: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 473

BRAZIL: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 474

BRAZIL: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 475

BRAZIL: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 476

MEXICO: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 477

MEXICO: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 478

MEXICO: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 479

MEXICO: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 480

MEXICO: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 481

MEXICO: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 482

MEXICO: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 483

MEXICO: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 484

MEXICO: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 485

REST OF LATIN AMERICA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 486

REST OF LATIN AMERICA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 487

REST OF LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 488

REST OF LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 489

REST OF LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 490

REST OF LATIN AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 491

REST OF LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 492

REST OF LATIN AMERICA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 493

REST OF LATIN AMERICA: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 494

MIDDLE EAST: KEY MACROECONOMIC INDICATORS

TABLE 495

MIDDLE EAST: EPIGENETICS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 496

MIDDLE EAST: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 497

MIDDLE EAST: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 498

MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 499

MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 500

MIDDLE EAST: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 501

MIDDLE EAST: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 502

MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 503

MIDDLE EAST: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 504

MIDDLE EAST: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 505

GCC COUNTRIES: EPIGENETICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 506

GCC COUNTRIES: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 507

GCC COUNTRIES: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 508

GCC COUNTRIES: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 509

GCC COUNTRIES: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 510

GCC COUNTRIES: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 511

GCC COUNTRIES: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 512

GCC COUNTRIES: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 513

GCC COUNTRIES: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 514

GCC COUNTRIES: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 515

SAUDI ARABIA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 516

SAUDI ARABIA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 517

SAUDI ARABIA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 518

SAUDI ARABIA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 519

SAUDI ARABIA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 520

SAUDI ARABIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 521

SAUDI ARABIA: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 522

SAUDI ARABIA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 523

SAUDI ARABIA: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 524

UAE: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 525

UAE: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 526

UAE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 527

UAE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 528

UAE: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 529

UAE: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 530

UAE: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 531

UAE: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 532

UAE: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 533

REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 534

REST OF GCC COUNTRIES: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 535

REST OF GCC COUNTRIES: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 536

REST OF GCC COUNTRIES: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 537

REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 538

REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 539

REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 540

REST OF GCC COUNTRIES: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 541

REST OF GCC COUNTRIES: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 542

REST OF MIDDLE EAST: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 543

REST OF MIDDLE EAST: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 544

REST OF MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 545

REST OF MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 546

REST OF MIDDLE EAST: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 547

REST OF MIDDLE EAST: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 548

REST OF MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 549

REST OF MIDDLE EAST: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 550

REST OF MIDDLE EAST: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 551

AFRICA: KEY MACROECONOMIC INDICATORS

TABLE 552

AFRICA: EPIGENETICS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 553

AFRICA: EPIGENETICS MARKET FOR OFFERING, BY TYPE, 2023–2030 (USD MILLION)

TABLE 554

AFRICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 555

AFRICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 556

AFRICA: EPIGENETICS MARKET, BY METHOD, 2023–2030 (USD MILLION)

TABLE 557

AFRICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 558

AFRICA: EPIGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 559

AFRICA: EPIGENETICS PRODUCT MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 560

AFRICA: EPIGENETICS SERVICE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 561

OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN EPIGENETICS MARKET, JANUARY 2022–JULY 2025

TABLE 562

EPIGENETICS MARKET: DEGREE OF COMPETITION

TABLE 563

EPIGENETICS MARKET: REGION FOOTPRINT

TABLE 564

EPIGENETICS MARKET: OFFERING FOOTPRINT

TABLE 565

EPIGENETICS MARKET: METHOD FOOTPRINT

TABLE 566

EPIGENETICS MARKET: TECHNOLOGY FOOTPRINT

TABLE 567

EPIGENETICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES

TABLE 568

EPIGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES

TABLE 569

EPIGENETICS MARKET: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025

TABLE 570

EPIGENETICS MARKET: DEALS, JANUARY 2022–JULY 2025

TABLE 571

EPIGENETICS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–JULY 2025

TABLE 572

THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW

TABLE 573

THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED

TABLE 574

THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025

TABLE 575

THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JULY 2025

TABLE 576

ILLUMINA, INC.: COMPANY OVERVIEW

TABLE 577

ILLUMINA, INC.: PRODUCTS OFFERED

TABLE 578

ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025

TABLE 579

ILLUMINA, INC.: DEALS, JANUARY 2022–JULY 2025

TABLE 580

MERCK KGAA: COMPANY OVERVIEW

TABLE 581

MERCK KGAA: PRODUCTS OFFERED

TABLE 582

PACBIO: COMPANY OVERVIEW

TABLE 583

PACBIO: PRODUCTS OFFERED

TABLE 584

PACBIO: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025

TABLE 585

PACBIO: DEALS, JANUARY 2022–JULY 2025

TABLE 586

PACBIO: EXPANSIONS, JANUARY 2022– JULY 2025

TABLE 587

DANAHER: COMPANY OVERVIEW

TABLE 588

DANAHER: PRODUCTS OFFERED

TABLE 589

DANAHER: DEALS, JANUARY 2022–JULY 2025

TABLE 590

BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW

TABLE 591

BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED

TABLE 592

ACTIVE MOTIF: COMPANY OVERVIEW

TABLE 593

ACTIVE MOTIF: PRODUCTS OFFERED

TABLE 594

ACTIVE MOTIF: DEALS, JANUARY 2022–JULY 2025

TABLE 595

NEW ENGLAND BIOLABS: COMPANY OVERVIEW

TABLE 596

NEW ENGLAND BIOLABS: PRODUCTS OFFERED

TABLE 597

NEW ENGLAND BIOLABS: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025

TABLE 598

NEW ENGLAND BIOLABS: DEALS, JANUARY 2022–JULY 2025

TABLE 599

QIAGEN: COMPANY OVERVIEW

TABLE 600

QIAGEN: PRODUCTS OFFERED

TABLE 601

QIAGEN: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025

TABLE 602

ZYMO RESEARCH CORPORATION: COMPANY OVERVIEW

TABLE 603

ZYMO RESEARCH CORPORATION: PRODUCTS OFFERED

TABLE 604

ZYMO RESEARCH CORPORATION: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025

TABLE 605

ZYMO RESEARCH CORPORATION: EXPANSIONS, JANUARY 2022–JULY 2025

TABLE 606

ZYMO RESEARCH CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022–JULY 2025

TABLE 607

REVVITY: COMPANY OVERVIEW

TABLE 608

REVVITY: PRODUCTS OFFERED

TABLE 609

REVVITY: DEALS, JANUARY 2022–JULY 2025

TABLE 610

HOLOGIC, INC. COMPANY OVERVIEW

TABLE 611

HOLOGIC, INC.: PRODUCTS OFFERED

TABLE 612

F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW

TABLE 613

F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED

TABLE 614

PROMEGA CORPORATION: COMPANY OVERVIEW

TABLE 615

PROMEGA CORPORATION: PRODUCTS OFFERED

TABLE 616

EPIGENTEK GROUP INC.: COMPANY OVERVIEW

TABLE 617

EPIGENTEK GROUP INC.: PRODUCTS OFFERED

TABLE 618

EPICYPHER: COMPANY OVERVIEW

TABLE 619

FIOS GENOMICS: COMPANY OVERVIEW

TABLE 620

GENOMESCAN: COMPANY OVERVIEW

TABLE 621

CREATIVE BIOGENE: COMPANY OVERVIEW

TABLE 622

BPS BIOSCIENCE, INC.: COMPANY OVERVIEW

TABLE 623

ABNOVA CORPORATION: COMPANY OVERVIEW

TABLE 624

CREATIVE DIAGNOSTICS: COMPANY OVERVIEW

TABLE 625

BIOMODAL: COMPANY OVERVIEW

TABLE 626

INTEGRATED DNA TECHNOLOGIES, INC.: COMPANY OVERVIEW

TABLE 627

NOVOGENE CO., LTD.: COMPANY OVERVIEW

LIST OF FIGURES

FIGURE 1

EPIGENETICS MARKET SEGMENTATION AND REGIONAL SCOPE

FIGURE 2

EPIGENETICS MARKET: YEARS CONSIDERED

FIGURE 3

EPIGENETICS MARKET: RESEARCH DESIGN

FIGURE 4

EPIGENETICS MARKET: BREAKDOWN OF PRIMARIES

FIGURE 5

EPIGENETICS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024

FIGURE 6

EPIGENETICS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH), 2024

FIGURE 7

ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE ANALYSIS, 2024

FIGURE 8

EPIGENETICS MARKET: INSIGHTS FROM PRIMARY EXPERTS

FIGURE 9

SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH

FIGURE 10

EPIGENETICS MARKET: CAGR PROJECTIONS

FIGURE 11

EPIGENETICS MARKET: DATA TRIANGULATION

FIGURE 12

EPIGENETICS MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)

FIGURE 13

EPIGENETICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)

FIGURE 14

EPIGENETICS MARKET, BY METHOD, 2025 VS. 2030 (USD MILLION)

FIGURE 15

EPIGENETICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)

FIGURE 16

EPIGENETICS PRODUCT MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)

FIGURE 17

EPIGENETICS SERVICE MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)

FIGURE 18

GEOGRAPHIC ANALYSIS OF EPIGENETICS MARKET

FIGURE 19

TECHNOLOGICAL ADVANCEMENTS IN EPIGENETICS RESEARCH TO DRIVE MARKET GROWTH

FIGURE 20

DNA METHYLATION SEGMENT AND US LED NORTH AMERICAN EPIGENETICS MARKET IN 2024

FIGURE 21

ACADEMIC & RESEARCH INSTITUTES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD

FIGURE 22

ASIA PACIFIC TO BE FASTEST-GROWING MARKET IN GLOBAL EPIGENETICS MARKET DURING FORECAST PERIOD

FIGURE 23

EPIGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 24

COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001–2022

FIGURE 25

NUMBER OF CANCER CASES IN US, 2019–2024

FIGURE 26

REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN EPIGENETICS MARKET

FIGURE 27

AVERAGE SELLING PRICE OF INSTRUMENTS, BY KEY PLAYER, 2024 (USD)

FIGURE 28

AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY KEY PLAYER, 2024 (USD)

FIGURE 29

AVERAGE SELLING PRICE OF ENZYMES, BY KEY PLAYER, 2024 (USD)

FIGURE 30

AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2024 (USD MILLION)

FIGURE 31

AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY REGION, 2024 (USD MILLION)

FIGURE 32

AVERAGE SELLING PRICE OF ENZYMES, BY REGION, 2024 (USD MILLION)

FIGURE 33

EPIGENETICS MARKET: VALUE CHAIN ANALYSIS

FIGURE 34

EPIGENETICS MARKET: ECOSYSTEM ANALYSIS

FIGURE 35

EPIGENETICS MARKET: INVESTMENT AND FUNDING SCENARIO, 2022–2025

FIGURE 36

EPIGENETICS MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024

FIGURE 37

EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS

FIGURE 38

INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING

FIGURE 39

KEY BUYING CRITERIA, BY END USER

FIGURE 40

EPIGENETICS MARKET: AI USE CASES

FIGURE 41

EPIGENETICS MARKET, BY OFFERING, 2023–2030 (MILLION UNITS)

FIGURE 42

NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT

FIGURE 43

ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT

FIGURE 44

EPIGENETICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024

FIGURE 45

EPIGENETICS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024

FIGURE 46

EV/EBITDA OF KEY VENDORS

FIGURE 47

YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS

FIGURE 48

EPIGENETICS MARKET: BRAND/PRODUCT COMPARISON

FIGURE 49

EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024

FIGURE 50

EPIGENETICS MARKET: COMPANY FOOTPRINT

FIGURE 51

EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024

FIGURE 52

THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)

FIGURE 53

ILLUMINA, INC.: COMPANY SNAPSHOT (2024)

FIGURE 54

MERCK KGAA: COMPANY SNAPSHOT (2024)

FIGURE 55

PACBIO: COMPANY SNAPSHOT (2024)

FIGURE 56

DANAHER: COMPANY SNAPSHOT (2024)

FIGURE 57

BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)

FIGURE 58

QIAGEN: COMPANY SNAPSHOT (2024)

FIGURE 59

REVVITY: COMPANY SNAPSHOT (2024)

FIGURE 60

HOLOGIC, INC.: COMPANY SNAPSHOT (2024)

FIGURE 61

F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)

Methodology

This research involved extensively using secondary sources, directories, and databases to gather valuable information for analyzing the global epigenetics market. In-depth interviews were conducted with various key respondents, including industry leaders, subject-matter experts (SMEs), C-level executives of major market players, and industry consultants, to obtain and verify critical qualitative and quantitative data and to evaluate the market's growth prospects. The global market size, estimated through secondary research, was then triangulated with inputs from primary research to determine the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the epigenetics market. The secondary sources used for this study include World Health Organization (WHO), World Intellectual Property Organization (WIPO), International Union of Biochmistry and Molecular Biology (IUBMB), National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), Centers for Disease Control and Prevention (CDC), American Cancer Society (ACS), American Society for Biochemistry and Molecular Biology (ASBMB), Canadian Society for Molecular Biosciences (CSMB), National Institute of Environmental Health Sciences (NIEHS), Canadian Institutes of Health Research (CIHR), Genome Canada, and Central Drugs Standard Control Organisation (CDSCO); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global epigenetics market, which was validated through primary research. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the epigenetics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Data Triangulation

After estimating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain precise statistics for all segments and subsegments, data triangulation and market breakdown procedures were used whenever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

Market Definition

Epigenetics involves assessing individual behaviors and environmental factors that may influence gene functions. Unlike genetic changes, epigenetic modifications can be reversed and do not alter the DNA sequence. The report provides both qualitative and quantitative analyses of various products and services used in epigenetics research by end users such as academic and research institutions, pharmaceutical and biotechnology companies, and hospitals and clinics.

Stakeholders

Contract research organizations (CROs)
Contract development and manufacturing organizations (CDMOs)
Pharmaceutical & biopharmaceutical companies
Life science companies
Academic & research institutes
Private research institutes
Venture capitalists & investors
Market research & consulting firms
Government associations
Medical institutions & universities
Hospitals & clinics

Report Objectives

To define, describe, and forecast the epigenetics market by offering, method, technology, application, end user (product), end user (service), and region
To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall epigenetics market
To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa
To profile the key players and analyze their market shares and core competencies2
To track and analyze competitive developments, such as product launches, agreements, partnerships, acquisitions, and R&D activities
To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the epigenetics market.

Key Questions Addressed by the Report

Who are the key players in the epigenetics market?

Key players include Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), PacBio (US), Danaher (US), Merck KGaA (Germany), Active Motif, Inc. (US), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Revvity (US), Qiagen (Germany), New England Biolabs (US), Zymo Research (US), Hologic Diagenode (US), F. Hoffmann-La Roche Ltd. (Switzerland), and Epigentek Group Inc. (US).

Which offerings segment dominates the epigenetics market?

The kits & reagents segment held the largest market share in 2024, driven by increasing pharmaceutical investment and government support for epigenetics development.

Which method segment dominates the epigenetics market?

The DNA methylation segment dominated the market in 2024 due to its effectiveness in cancer research.

Which technique segment dominates the epigenetics market?

The NGS (Next-Generation Sequencing) segment led the market in 2024, attributed to the growing number of companies involved in epigenetics sequencing.

What is the market size for the epigenetics market?

The market is projected to grow from USD 2.24 billion in 2025 to USD 4.29 billion by 2030, with a CAGR of 11.3% during the forecast period.

Epigenetics Market by Product & Service (Enzymes, Kits & Reagents (Antibodies), Software), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR), Application (Oncology, Immunology, Developmental Biology), End User - Global Forecast to 2030

OVERVIEW

KEY TAKEAWAYS

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

MARKET DYNAMICS

Driver: Declining sequencing costs and time

Restraint: Limited applications of epigenomic data in toxicology

Opportunity: Emerging applications of epigenetics

Challenge: Concerns regarding quality of antibodies

Epigenetics Market: COMMERCIAL USE CASES ACROSS INDUSTRIES

MARKET ECOSYSTEM

MARKET SEGMENTS

Epigenetics Market, By Offering

Epigenetics Market, By Technology

Epigenetics Market, By Application

REGION

Asia Pacific to be fastest-growing region in global epigenetics market during forecast period

Epigenetics Market: COMPANY EVALUATION MATRIX

KEY MARKET PLAYERS

MARKET SCOPE

WHAT IS IN IT FOR YOU: Epigenetics Market REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS

RECENT DEVELOPMENTS

Table of Contents

Methodology

Secondary Research

Primary Research

Market Size Estimation

Data Triangulation

Market Definition

Stakeholders

Report Objectives

Key Questions Addressed by the Report

Who are the key players in the epigenetics market?

Which offerings segment dominates the epigenetics market?

Which method segment dominates the epigenetics market?

Which technique segment dominates the epigenetics market?

What is the market size for the epigenetics market?

TABLE OF CONTENTS

METHODOLOGY

Adjacent Markets

Personalize This Research

Let Us Help You

Growth opportunities and latent adjacency in Epigenetics Market